Phase I study of AG2034, a targeted GARFT inhibitor,...

Cancer Chemotherapy and Pharmacology 2000 / 04 Vol. 45; Iss. 5

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

John D. Roberts, Stephen Shibata, Darcy V. Spicer, Howard L. McLeod, Mary Beth Tombes, Brenda Kyle, Mary Carroll, Beth Sheedy, Mary A. Collier, Yazdi K. Pithavala, Linda J. Paradiso, Neil J. Clendenin
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
45
Language:
english
Pages:
5
DOI:
10.1007/s002800051012
Date:
April, 2000
File:
PDF, 95 KB
english, 2000
Conversion to is in progress
Conversion to is failed